Analysts: CBS May Buy Back Shares and 4 More Research Notes to Review Now

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Acadia Pharmaceuticals (NASDAQ:ACAD): Roth Capital is convinced that a Phase III trial of ACADIA’s pimavanserin for psychosis in Parkinson’s disease showed strong efficacy results supporting the $1 billion potential for the drug. The firm keeps its Buy rating and an $11 price target on the stock.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

ACAD

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business